RECOVER-TLC released a public update on four major long COVID treatment trials. Many patients are asking the same question: how close are we to an approved treatment?In this episode, I break down how RECOVER-TLC chooses treatments to study, why the research process takes so long, and where each of the four current trials stands right now. I’ll also explain what this progress realistically means for people living with long COVID—without hype and without false hope.This is for people who want a clear, honest explanation of long COVID research and timelines, and who want to understand how close—or far—we really are from approved treatments.In this episode:-Why approved long COVID treatments take so long-How RECOVER-TLC selects and designs clinical trials-Updates on baricitinib, low-dose naltrexone, GLP-1 agonists, and stellate ganglion block-What this research means for patients right nowChapters:00:00 Understanding Long COVID and Research Delays01:43 The Process of Choosing Targets03:49 Designing Clinical Trials07:32 Join the Community08:25 Baricitinib09:54 Low Dose Naltrexone (LDN)11:08 Semaglutide: Exploring GLP-1 Treatments14:08 Stellate Ganglion Block16:52 Key Takeaways and Future Outlook#longCOVID #COVID #fatigue #MECFS #POTS #medicine #science #RECOVERTLC #NIH #FDA #NIAIDSupport the showSubscribe for free written summaries of each episode, resources, and more. LongCovidMD.substack.com/subscribe Support by donating at BuyMeACoffee